Wegovy approved by NICE for heart and stroke prevention

A decision by the UK’s health cost regulator could change how obesity and heart disease are treated together. The National Institute for Health and Care Excellence has recommended Wegovy, a drug developed by Novo Nordisk, for use on the NHS to reduce the risk of heart attacks and strokes. This is the first time a weight-loss drug in this class has been backed for cardiovascular prevention in England, expanding its role beyond managing body weight.

The recommendation targets a specific group of patients. Around 1.2 million people in England who have both obesity and existing cardiovascular disease could qualify for the treatment. For these patients, the drug is not just about losing weight. It is meant to lower the chances of serious events such as heart attacks and strokes, which remain leading causes of death.

What the clinical trial showed

The decision is based on data from the SELECT trial, which followed more than 17,600 patients. Participants who received Wegovy experienced a 20 percent reduction in major cardiovascular events compared to those given a placebo. That figure stands out because it reflects outcomes that matter directly to patients, not just changes in weight or blood sugar levels.

The study focused on people who were already at high risk due to existing heart disease. By targeting this group, researchers could measure whether the drug offered protection beyond standard treatments such as statins or blood pressure medication.

How Wegovy works in the body

Wegovy belongs to a class of drugs known as GLP-1 receptor agonists. These medications mimic a hormone that regulates appetite and blood sugar. Patients tend to feel full sooner and eat less, which leads to weight loss over time. The same pathway also affects how the body handles glucose and may influence inflammation, both of which are linked to heart health.

Doctors have used similar drugs for diabetes for years. What has changed is the growing evidence that they can reduce serious cardiovascular events, even in people who do not have diabetes. That shift has pushed regulators to consider them as part of broader heart disease management.

What this means for the NHS

Introducing Wegovy for this purpose will require careful planning. The NHS will need to decide how to prioritize patients, manage supply, and monitor outcomes. Cost remains a factor, as these treatments are more expensive than many existing medications. NICE’s approval signals that the benefits justify the expense for the selected group, based on current evidence.

There is also the question of access. Demand for GLP-1 drugs has grown quickly, and supply has not always kept up. Expanding their use to cardiovascular prevention could increase pressure on availability, especially in the early stages of rollout.

The recommendation places the UK among the first countries to adopt this approach at a national level. As more data becomes available, other health systems may review similar policies. For now, the focus will be on how well the drug performs in real-world NHS settings, where patient needs and conditions vary widely.